Prevalence and duration of anti-SARS-CoV-2 antibodies in healthcare workers
Danish Medical Journal
; 69(5), 2022.
Article
in English
| GIM | ID: covidwho-1989656
ABSTRACT
Introduction. Knowledge of the seroprevalence and duration of antibodies against SARS-CoV-2 was needed in the early phases of the COVID-19 pandemic and is still necessary for policy makers and healthcare professionals. This information allows us to better understand the risk of reinfection in previously infected individuals. Methods. We investigated the prevalence and duration of detectable antibodies against SARS-CoV-2 in sequentially collected samples from 379 healthcare professionals. Results. SARS-CoV-2 seroprevalence at inclusion was 5.3% (95% confidence interval (CI) 3.3-8.0%) and 25% of seropositive participants reverted during follow-up. At the end of follow-up, the calculated probability of having detectable antibodies among former seropositive participants was 72.2% (95% CI 54.2-96.2%). Conclusion. Antibodies against SARS-CoV-2 were detectable in a subset of infected individuals for a minimum of 39 weeks.
seroprevalence; human diseases; viral diseases; disease prevalence; antibodies; health care; health care workers; infectious diseases; pandemics; reinfection; coronavirus disease 2019; Severe acute respiratory syndrome coronavirus 2; man; Severe acute respiratory syndrome-related coronavirus; Betacoronavirus; Coronavirinae; Coronaviridae; Nidovirales; positive-sense ssRNA Viruses; ssRNA Viruses; RNA Viruses; viruses; Homo; Hominidae; primates; mammals; vertebrates; Chordata; animals; eukaryotes; SARS-CoV-2; viral infections; communicable diseases
Search on Google
Collection:
Databases of international organizations
Database:
GIM
Type of study:
Observational study
Language:
English
Journal:
Danish Medical Journal
Year:
2022
Document Type:
Article
Similar
MEDLINE
...
LILACS
LIS